Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia
Journal of Urology - Netherlands
doi 10.1016/j.juro.2012.11.003
Full Text
Open PDFAbstract
Available in full text
Categories
Date
April 1, 2013
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)